Construction of Fe3O4/SiO2/chitosan-grafted-poly(N-vinylcaprolactam) magnetic nanocomposite and their application in simultaneous extraction of Trans-resveratrol and its metabolites from rat plasma

A novel magnetic nanocomposite of chitosan-grafted-poly(N-vinylcaprolactam) (Fe3O4/SiO2/CHT-g-PNVCL MNC) were synthesized. Chitosan was prepared from shrimp shells Penaeus monodon by a green deacetylation approach. N-vinylcaprolactam was first polymerized on the surface of Fe3O4 magnetic nanoparticles using surface-initiated atom transfer radical polymerization. Then, the Fe3O4 nanoparticles modified with carboxyl-terminated- poly(N-vinylcaprolactam) was grafted onto chitosan. Various techniques were used to characterize of physicochemical properties of synthesized nanomaterials. The application of Fe3O4/SiO2/CHT-g-PNVCL MNC was utilized as a novel adsorbent for the simultaneous extraction of trans-resveratrol and its major phase II metabolites from rat plasma. A qualitative analysis was performed using ultra-performance liquid chromatography triple-quadrupole tandem mass spectrometry. Response surface methodology based on central composite design was used to optimize the extraction procedure including pH, amount of adsorbent, extraction time, desorption time, and volume of elution solvent. The established quantitative method succeeded in satisfying FDA requirements regarding biological analysis methods. The results of the validation of the method indicated its acceptable accuracy (−4.4 to 6.9%), linearity (r > 0.995), precision (CV < 6.3%), and stability. The lower limits of quantification of the proposed method achieved were 1.23–1.68 ngmL−1 for target analytes. The information obtained from the method validation has been used to estimate the expanded uncertainty for the determination of trans-resveratrol in rat plasma samples following orally administered trans-resveratrol. The method was applied to study the pharmacokinetics, metabolism, and bioavailability of trans-resveratrol in healthy rats following a single oral or intravenous dose.